Opus Genetics
IRD
59 hedge funds and large institutions have $55.9M invested in Opus Genetics in 2025 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 19 increasing their positions, 8 reducing their positions, and 5 closing their positions.
1,024% more call options, than puts
Call options by funds: $191K | Put options by funds: $17K
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
138% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 8
74% more capital invested
Capital invested by funds: $32.1M → $55.9M (+$23.8M)
23% more funds holding
Funds holding: 48 → 59 (+11)
8.55% more ownership
Funds ownership: 31.78% → 40.33% (+8.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.52M |
| 2 |
Millennium Management
New York
|
+$4.07M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.91M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.99M |
| 5 |
MBAM
Mink Brook Asset Management
West Palm Beach,
Florida
|
+$868K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Voss Capital
Houston,
Texas
|
-$245K |
| 2 |
Renaissance Technologies
New York
|
-$96.4K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$56.9K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$48.3K |
| 5 |
HF
HRT Financial
New York
|
-$34K |
IRD Hedge Fund Activity: Q4 2025 in Review
59 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q4 2025, worth a combined $55.9M — up 74% from $32.1M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new IRD positions and 5 closed out — a net gain of 11 holders — while 19 added to existing stakes and 8 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $5.52M. The largest seller was Voss Capital, cutting an estimated $245K.
- 59 institutional investors held Opus Genetics (IRD) as of Q4 2025, up from 48 in Q3 2025.
- Funds reported $55.9M of Opus Genetics stock for Q4 2025, up 74% quarter-over-quarter.
- 16 funds opened new Opus Genetics positions in Q4 2025 and 5 closed out, a net change of +11 holders.
- The largest Opus Genetics buyer in Q4 2025 was Balyasny Asset Management, an estimated $5.52M added.
- The largest Opus Genetics seller in Q4 2025 was Voss Capital, an estimated $245K sold.
Based on aggregated 13F filings for Q4 2025.